SCHEMBL22093049

SCHEMBL22093049

COc1cc(C(F)(F)F)nc(Cl)c1C(N)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
HPGD P15428 3/20 0.40
GAA P10253 2/20 0.40
RIPK2 O43353 2/20 0.39
IGF1R P08069 3/20 0.39
MAPT P10636 5/20 0.39
HSD17B10 Q99714 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 1/20 0.38
MEN1 O00255 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 2/20 0.37
PDE4B Q07343 2/20 0.37
CDK8 P49336 1/20 0.36
CDK19 Q9BWU1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22093031 0.87 MAPK1 (0.42) POLBHPGDIGF1RMAPTKMT2A
SCHEMBL22093090 0.81 ALDH1A1 (0.43) POLBHPGDGAAMAPTHSD17B10
SCHEMBL27176096 0.78 POLB (0.67) POLBHPGDGAARIPK2MAPT
SCHEMBL3546719 0.75 POLB (0.63) POLBHPGDGAAMAPTHSD17B10
SCHEMBL22093214 0.73 KDM4E (0.52) POLBIGF1RMAPTKMT2ASMN1; SMN2
SCHEMBL10363011 0.72 KDM4E (0.41) POLBHPGDIGF1RMAPTHSD17B10
SCHEMBL6217742 0.70 ALDH1A1 (0.61) POLBMAPTHSD17B10KMT2ASMN1; SMN2
SCHEMBL30586203 0.70 ALDH1A1 (0.61) POLBMAPTHSD17B10KMT2ASMN1; SMN2
SCHEMBL3536841 0.70 POLB (0.46) POLBGAAMAPTKMT2ALMNA
SCHEMBL31558179 0.70 CASP1 (0.42) POLBHSD17B10LMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 US disclosed
CN-119528824-A 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2025-02-28 CN disclosed
CN-113166078-B 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2024-11-19 CN disclosed
WO-2023066283-A1 METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-04-27 WO disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 US disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 CN disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A POLB 114/4885HPGD 1384/4885GAA 1692/4885
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A POLB 114/4885HPGD 1384/4885GAA 1692/4885
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A POLB 114/4885HPGD 1384/4885GAA 1692/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A POLB 114/4885HPGD 1384/4885GAA 1692/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A POLB 114/4885HPGD 1384/4885GAA 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.